



Corrigendum: Top-Down Proteomics of Human Saliva Highlights Anti-inflammatory, Antioxidant, and Antimicrobial Defense Responses in Alzheimer Disease

Cristina Contini^{1†}, Alessandra Olianas^{1†}, Simone Serrao¹, Carla Deriu¹, Federica lavarone^{2,3}, Mozhgan Boroumand⁴, Alessandra Bizzarro⁵, Alessandra Lauria⁵, Gavino Faa⁶, Massimo Castagnola⁴, Irene Messana⁷, Barbara Manconi^{1*‡}, Carlo Masullo^{8‡} and Tiziana Cabras^{1‡}

OPEN ACCESS

Edited and reviewed by:

Rossen Donev, MicroPharm Ltd, United Kingdom

*Correspondence:

Barbara Manconi bmanconi@unica.it

[†]These authors have contributed equally to this work and share first authorship

[‡]These authors have contributed equally to this work and share last authorship

Specialty section:

This article was submitted to Neurogenomics, a section of the journal Frontiers in Neuroscience

Received: 18 July 2021 Accepted: 22 July 2021 Published: 13 August 2021

Citation:

Contini C, Olianas A, Serrao S,
Deriu C, Iavarone F, Boroumand M,
Bizzarro A, Lauria A, Faa G,
Castagnola M, Messana I, Manconi B,
Masullo C and Cabras T (2021)
Corrigendum: Top-Down Proteomics
of Human Saliva Highlights
Anti-inflammatory, Antioxidant, and
Antimicrobial Defense Responses in
Alzheimer Disease.
Front. Neurosci. 15:743596.
doi: 10.3389/fnins.2021.743596

¹ Dipartimento di Scienze della Vita e dell'Ambiente, Università di Cagliari, Cagliari, Italy, ² Dipartimento di Scienze Biotecnologiche di Base, Cliniche Intensivologiche e Perioperatorie, Università Cattolica del Sacro Cuore, Rome, Italy, ³ Fondazione Policlinico Universitario "A. Gemelli" – IRCCS, Rome, Italy, ⁴ Laboratorio di Proteomica, Centro Europeo di Ricerca sul Cervello, IRCCS Fondazione Santa Lucia, Rome, Italy, ⁵ UOC Continuità Assistenziale, Fondazione Policlinico Universitario "A. Gemelli" – IRCCS, Rome, Italy, ⁶ Dipartimento di Scienze Mediche e Sanità Pubblica, University of Cagliari, Cagliari, Italy, ⁷ Istituto di Scienze e Tecnologie Chimiche "Giulio Natta", Consiglio Nazionale delle Ricerche, Rome, Italy, ⁸ Dipartimento di Neuroscienze, Sez. Neurologia, Università Cattolica del Sacro Cuore, Rome, Italy

Keywords: Alzheimer disease, salivary proteomics, S100A, cystatins, α -defensins, thymosin β 4, antimicrobial peptides, oxidative stress

A Corrigendum on

Top-Down Proteomics of Human Saliva Highlights Anti-inflammatory, Antioxidant, and Antimicrobial Defense Responses in Alzheimer Disease

by Contini, C., Olianas, A., Serrao, S., Deriu, C., Iavarone, F., Boroumand, M., et al. (2021). Front. Neurosci. 15:668852. doi: 10.3389/fnins.2021.668852

In the original article, the Supplementary Table 4 and the Supplementary Figure 6, cited on page 6 in the original article, are missing from the Supplementary Materials. The corrected Supplementary Table 4 and Supplementary Figure 6 are shown below. The Supplementary Material of the original article has been updated.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Contini, Olianas, Serrao, Deriu, Iavarone, Boroumand, Bizzarro, Lauria, Faa, Castagnola, Messana, Manconi, Masullo and Cabras. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

1

TABLE S4 | XIC peak areas values (mean \pm SD) normalized on TPC, frequencies and p-values obtained by statistical analysis by comparing the three patients' groups treated with different therapies by non-parametric ANOVA with the Krustal-Wallis test and Dunn's post test. p-values > 0.05 are not statistically significant (\bullet).

Peptide	XIC Peak Areas x $10^5 (\text{mean} \pm \text{SD})$ and Frequency				
	G1 (nr 19)	G2 (nr 8)	G3 (nr 8)	HC (nr 34)	ANOVA p value
α-defensin 1	2.2 ± 2.3 (19)	2.3 ± 1.8 (8)	0.6 ± 0.8 (5)	0.5 ± 0.6 (24)	p < 0.0001 (G1vs G3*, G2 vs G3*, G1 vs HC***, G2 vs HC**)
α -defensin 2	1.5 ± 1.5 (19)	1.5 ± 1.2 (7)	0.4 ± 0.6 (5)	0.4 ± 0.4 (27)	p = 0.0003 (G1vs G3*, G1 vs HC**, G2 vs HC*)
α-defensin 3	0.7 ± 0.5 (16)	0.8 ± 0.5 (8)	0.2 ± 0.4 (2)	0.2 ± 0.3 (17)	p < 0.0001 (G1vs G3*, G2 vs G3*, G1 vs HC***, G2 vs HC**)
α-defensin 4	0.2 ± 0.3 (8)	0.4 ± 0.2 (8)	0.04 ± 0.08 (2)	0.05 ± 0.1 (11)	p = 0.0004 (G1vs G2*, G2 vs G3**, G2 vs HC***)
Τβ4	0.5 ± 0.6 (14)	1.1 ± 0.9 (8)	0.2 ± 0.4 (3)	0.2 ± 0.4 (16)	p = 0.002 (G2vs G3**, G2 vs HC**)
Stath. 2P	8.8 ± 7.7 (19)	5.9 ± 4.4 (6)	11.0 ± 7.1 (8)	1.1 ± 0.9 (33)	p < 0.0001 (G1 vs HC***, G2vs HC*, G3 vs HC***)
Stath. Des1-9	0.5 ± 0.6 (16)	0.6 ± 0.9 (6)	0.8 ± 0.6 (7)	0.08 ± 0.1 (24)	p = 0.0002 (G1 vs HC**, G3 vs HC**)
P-C peptide	9.3 ± 5.1 (19)	8.6 ± 12.6 (6)	12.3 ± 6.9 (8)	$5.6 \pm 4.4 (34)$	p = 0.01 (G3 vs HC*)
Cyst. B tot	2.0 ± 2.2 (18)	1.9 ± 1.6 (8)	0.9 ± 1.2 (7)	9.3 ± 5.1 (27)	$p = 0.006 (G1vs HC^*, G2 vs HC^*)$
Cyst A	1.8 ± 1.6 (17)	2.9 ± 1.9 (8)	1.2 ± 0.9 (7)	1.0 ± 0.9 (29)	p = 0.02 (G2 vs HC*)
S100A8 tot	1.1 ± 1.5 (12)	0.9 ± 1.1 (6)	0.4 ± 0.5 (4)	$0.08 \pm 0.2(5)$	p < 0.0001 (G1 vs HC***, G2 vs HC**)
S100A8-SNO	1.1 ± 2.3 (9)	$0.7 \pm 1.0 (3)$	Not detected	Not detected	p < 0.0001 (G1 vs G3*, G1 vs HC***)
S100A9(S) tot	1.1 ± 1.5 (18)	0.9 ± 1.1 (7)	0.4 ± 0.5 (7)	05 ± 0.8 (16)	$p < 0.0001 (G1 \text{ vs HC}^{***}, G2 \text{ vs HC}^*)$

